Ranibizumab

Brand names: Nufymco · Active ingredient: Ranibizumab

In short: NUFYMCO is indicated for the treatment of patients with:

Forms & strengthsSingle-dose glass vial designed to provide 0.05 mL for intravitreal injection. Clear and colorless to pale yellow 10 mg/mL solution (0.5 mg) Clear and colorless to pale yellow 6 mg/mL solution (0.3 mg)
LabelZydus Pharmaceuticals USA Inc.
Label updatedNov 09, 2026

What is Ranibizumab used for?

NUFYMCO is indicated for the treatment of patients with:

Ranibizumab dosage

FOR OPHTHALMIC INTRAVITREAL INJECTION.

Vials: A 5-micron sterile filter needle (19-gauge x 1-1/2 inch), a 1-mL Luer lock syringe and a 30-gauge x ½ inch sterile injection needle are needed but not included.

NUFYMCO 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).

Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment. In the 9 months after three initial monthly doses, less frequent dosing with 4-5 doses on average is expected to maintain visual acuity while monthly dosing may be expected to result in an additional average 1-2 letter gain. Patients should be assessed regularly .

Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses. Compared with continued monthly dosing, dosing every 3 months over the next 9 months will lead to an approximate 5-letter (1-line) loss of visual acuity benefit, on average. Patients should be assessed regularly .

NUFYMCO 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).

In Studies RVO-1 and RVO-2, patients received monthly injections of ranibizumab for 6 months. In spite of being guided by optical coherence tomography and visual acuity re-treatment criteria, patients who were then not treated at Month 6 experienced on average, a loss of visual acuity at Month 7, whereas patients who were treated at Month 6 did not. Patients should be treated monthly .

NUFYMCO 0.3 mg (0.05 mL of 6 mg/mL solution) is recommended to be administered by intravitreal injection once a month (approximately 28 days).

NUFYMCO 0.5 mg (0.05 mL of 10 mg/mL solution) is recommended to be initially administered by intravitreal injection once a month (approximately 28 days) for up to 3 months. Patients may be retreated if needed .

Vial:

Using aseptic technique, all of the NUFYMCO vial contents are withdrawn through a 5-micron (19‑gauge x 1-1/2 inch), sterile filter needle attached to a 1 mL syringe (not included). The filter needle should be discarded after withdrawal of the vial contents and should not be used for intravitreal injection. The filter needle should be replaced with a sterile 30-gauge x 1/2 inch needle for the intravitreal injection.

Use aseptic technique to carry out the following preparation steps:

1. …

How to take Ranibizumab — instructions & advice from the label

Advise patients that in the days following NUFYMCO administration, patients are at risk of developing endophthalmitis and retinal vasculitis with or without occlusion. If the eye becomes red, sensitive to light, painful, or develops a change in vision, advise the patient to seek immediate care from an ophthalmologist

Warnings & precautions

Do not take this medicine if: NUFYMCO is contraindicated in patients with ocular or periocular infections.

NUFYMCO is contraindicated in patients with known hypersensitivity to ranibizumab products or any of the excipients in NUFYMCO. Hypersensitivity reactions may manifest as severe intraocular inflammation.

Intravitreal injections, including those with ranibizumab products, have been associated with endophthalmitis and retinal detachments. Proper aseptic injection technique should always be used when administering NUFYMCO. In addition, patients should be monitored following the injection to permit early treatment should an infection occur .

Increases in intraocular pressure have been noted both pre-injection and post-injection (at 60 minutes) while being treated with ranibizumab products. Monitor intraocular pressure prior to and following intravitreal injection with NUFYMCO and manage appropriately .

Although there was a low rate of arterial thromboembolic events (ATEs) observed in the ranibizumab clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. Arterial thromboembolic events are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).

Neovascular (Wet) Age-Related Macular Degeneration

The ATE rate in the three controlled neovascular AMD studies (AMD-1, AMD-2, AMD-3) during the first year was 1.9% (17 of 874) in the combined group of patients treated with 0.3 mg or 0.5 mg ranibizumab compared with 1.1% (5 of 441) in patients from the control arms . In the second year of Studies AMD-1 and AMD-2, the ATE rate was 2.6% (19 of 721) in the combined group of ranibizumab-treated patients compared with 2.9% (10 of 344) in patients from the control arms. …

Ranibizumab side effects

The following adverse reactions are discussed in greater detail in other sections of the label:

Endophthalmitis and Retinal Detachments

Increases in Intraocular Pressure

Thromboembolic Events

Fatal Events in patients with DME and DR at baseline

Serious adverse reactions related to the injection procedure have occurred in < 0.1% of intravitreal injections, including endophthalmitis , rhegmatogenous retinal detachment, and iatrogenic traumatic cataract.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data below reflect exposure to 0.5 mg ranibizumab in 440 patients with neovascular AMD in Studies AMD-1, AMD-2, and AMD-3; in 259 patients with macular edema following RVO. The data also reflect exposure to 0.3 mg ranibizumab in 250 patients with DME and DR at baseline .

Safety data observed in 224 patients with mCNV, as well as Studies AMD-4 and D-3, were consistent with these results. On average, the rates and types of adverse reactions in patients were not significantly affected by dosing regimen.

Ocular Reactions

Table 1 shows frequently reported ocular adverse reactions in ranibizumab-treated patients compared with the control group. …

Drug interactions

Drug interaction studies have not been conducted with ranibizumab products.

Ranibizumab intravitreal injection has been used adjunctively with PDT. Twelve of 105 (11%) patients with neovascular AMD developed serious intraocular inflammation; in 10 of the 12 patients, this occurred when ranibizumab was administered 7 days (± 2 days) after PDT.

About this medicine

Ranibizumab-leyk is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment designed for intraocular use. Ranibizumab-leyk binds to and inhibits the biologic activity of human vascular endothelial growth factor A (VEGF-A). Ranibizumab-leyk, which lacks an Fc region, has a molecular weight of approximately 48 kilodaltons and is produced by an E. coli expression system.

NUFYMCO (ranibizumab-leyk) injection is a sterile, clear and colorless to pale yellow solution in a single-dose glass vial for intravitreal injection. NUFYMCO is supplied as a sterile, preservative-free solution in a single-dose container designed to deliver 0.05 mL of 10 mg/mL ranibizumab-leyk (0.5 mg dose vial) or 6 mg/mL ranibizumab-leyk (0.3 mg dose vial) aqueous solution with 10 mM histidine HCl, 10% α,α- trehalose dihydrate, 0.01% polysorbate 20, pH 5.5.

How it works: Ranibizumab products bind to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF110. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 05ed75bc-ae21-480b-9be4-cbc51689dd8a. Read the full official label on DailyMed.